Research map: The Impact of PCSK9 Inhibitors on Circulatory Inflammation

Back to the article

Papers in this map

  1. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients · Stephen James Nicholls · 2016 · 1182 citations · Cited by this paper
  2. Endovenous Radiofrequency Ablation for Varicose Veins · 2026 · Related
  3. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates · Kiran Musunuru · 2021 · 806 citations · Cited by this paper
  4. Prognostic Value of Persistent Microvascular Obstruction on Follow-Up Cardiac MRI After Reperfused STEMI · 2026 · Related
  5. Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis · Kun Wang · 2020 · 783 citations · Cited by this paper
  6. Smartphone-Based Remote Monitoring for Cardiac Implantable Electronic Devices · 2026 · Related
  7. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease · Antonio Abbate · 2020 · 748 citations · Cited by this paper
  8. Clinical Outcomes of Drug-Coated Balloon Following Directional Coronary Atherectomy in Acute vs Chronic Coronary Syndrome · 2026 · Related
  9. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction · Lorenz Räber · 2022 · 628 citations · Cited by this paper
  10. Angiography-Derived Index of Microcirculatory Resistance Predicts Microvascular Obstruction and Infarct Size in Patients With STEMI · 2026 · Related
  11. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease · Michelle L. O’Donoghue · 2022 · 597 citations · Cited by this paper
  12. Diagnosing Transthyretin Cardiac Amyloidosis in Japan · 2026 · Related
  13. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer · Xinjian Liu · 2020 · 515 citations · Cited by this paper
  14. Trends in Cardiovascular Diseases Burden in China, 1990-2023 · 2026 · Related
  15. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction · Stephen James Nicholls · 2022 · 464 citations · Cited by this paper
  16. Straining During Defecation or Gut Environment · 2026 · Related
  17. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease · Michelle L. O’Donoghue · 2022 · 414 citations · Cited by this paper
  18. Post-TAVR Conduction Disturbances · 2026 · Related
  19. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials · Bariş Gencer · 2020 · 323 citations · Cited by this paper
  20. Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study · 2025 · Related
  21. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial · Kausik Kumar Ray · 2023 · 322 citations · Cited by this paper
  22. Inflammatory and Cholesterol Risk in the FOURIER Trial · Erin Ann Bohula · 2018 · 281 citations · Cited by this paper
  23. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1 · Zufeng Ding · 2019 · 256 citations · Cited by this paper
  24. PCSK9 induces a pro-inflammatory response in macrophages · Chiara Ricci · 2018 · 230 citations · Cited by this paper
  25. The Multifaceted Biology of PCSK9 · Nabil Georges Seidah · 2021 · 230 citations · Cited by this paper
  26. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice · Christine Landlinger · 2017 · 228 citations · Cited by this paper
  27. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials · Kausik Kumar Ray · 2022 · 225 citations · Cited by this paper
  28. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 · Christie Mitchell Ballantyne · 2023 · 216 citations · Cited by this paper
  29. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia · Raul Dias Santos · 2020 · 198 citations · Cited by this paper
  30. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE · Prakriti Gaba · 2023 · 187 citations · Cited by this paper
  31. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor · Douglas G. Johns · 2023 · 168 citations · Cited by this paper
  32. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement · George A. Mensah · 2025 · 164 citations · Cited by this paper
  33. Targeting PCSK9 to tackle cardiovascular disease · Sandra Hummelgaard · 2023 · 147 citations · Cited by this paper
  34. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment · Lotte C.A. Stiekema · 2018 · 142 citations · Cited by this paper
  35. PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia · Xianwei Wang · 2020 · 119 citations · Cited by this paper
  36. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction · Lorenzo Da Dalt · 2021 · 118 citations · Cited by this paper
  37. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line · Massimiliano Ruscica · 2015 · 112 citations · Cited by this paper
  38. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9 · Hyunduk Jang · 2019 · 102 citations · Cited by this paper
  39. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial · R. Scott Wright · 2024 · 98 citations · Cited by this paper

Source: OpenAlex (CC0)